Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Philipps University Marburg Medical Center |
---|---|
Information provided by: | Philipps University Marburg Medical Center |
ClinicalTrials.gov Identifier: | NCT00202072 |
The purpose of this study is to determine whether mucin is increased during pulmonay exacerbations in adult patients with cystic fibrosis (CF).
Condition |
---|
Cystic Fibrosis |
Study Type: | Observational |
Study Design: | Natural History, Longitudinal, Defined Population, Retrospective Study |
Estimated Enrollment: | 25 |
Study Start Date: | January 2004 |
Estimated Study Completion Date: | September 2005 |
CF is typically associated with mucus hypersecretion in the airways. In health, mucin is the major macromolecular component and is responsible for the protective and clearance properties of the mucus gel. In a recent study we found that mucins are decreased in the sputum of adult CF patients.
In this study we want to investigate the differences on the mucin and DNA quantity and quality of airway secretions in during pulmoanry exacerbation.We hypothesize that during an exacerbation the mucin and DNA amount is increasing. The aim of this study is to evaluate the molecular (mucins) and structure properties (mucin-DNA-network) of the airway secretions in CF related to the severity of the disease. We characterize sputum composition of patients with pulmonary exacerbations. Using gel electrophoresis and dot-blot with specific antibodies we will analyze MUC5AC and MUC5B mucins. DNA amount will be measured by microfluorimetry.
With the laser scanning confocal microscopy the mucin-DNA-network will be evaluated.
The significance of these studies is that they will give us novel information about the pathogenesis of chronic inflammatory airway diseases, provide tools for assessing the progression of lung disease, and most critically, will identify novel opportunities and targets for therapeutic intervention.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
-
Contact: Markus O Henke, MD | 06421 ext 2866041 | markus.henke@staff.uni-marburg.de |
Germany | |
Pediatric department, CF center, University Giessen | Recruiting |
Giessen, Germany | |
Contact: Hermann Lindemann, MD 0641/99 ext 43430 Hermann.Lindemann@paediat.med.uni-giessen.de | |
Pediatric department, CF center, University Marburg | Recruiting |
Marburg, Germany | |
Contact: Markus O Henke, MD 06421 ext 2866041 markus.henke@staff.uni-marburg.de |
Principal Investigator: | Markus O Henke, MD | Philipps University Marburg Medical Center |
Study ID Numbers: | 208/03 |
Study First Received: | September 12, 2005 |
Last Updated: | September 12, 2005 |
ClinicalTrials.gov Identifier: | NCT00202072 History of Changes |
Health Authority: | Germany: Ethics Commission |
lung airway pulmonary exacerbation mucus |
Digestive System Diseases Genetic Diseases, Inborn Respiratory Tract Diseases Cystic Fibrosis |
Fibrosis Lung Diseases Infant, Newborn, Diseases Pancreatic Diseases |
Pathologic Processes Digestive System Diseases Genetic Diseases, Inborn Respiratory Tract Diseases Cystic Fibrosis |
Fibrosis Lung Diseases Infant, Newborn, Diseases Pancreatic Diseases |